Clinical Development Times for Biosimilars in the United States.
暂无分享,去创建一个
[1] A. Kesselheim,et al. Why Are Biosimilars Not Living up to Their Promise in the US? , 2019, AMA journal of ethics.
[2] Jonathan J. Darrow,et al. The US Biosimilar Market: Stunted Growth and Possible Reforms , 2018, Clinical pharmacology and therapeutics.
[3] V. Azevedo,et al. The biosimilars journey: current status and ongoing challenges , 2018, Drugs in context.
[4] J. Ross,et al. Obstacles to the Adoption of Biosimilars for Chronic Diseases. , 2017, JAMA.
[5] Michael A. Carrier,et al. Biologics: The New Antitrust Frontier , 2017 .
[6] L. Martin,et al. Trial watch: Clinical trial cycle times continue to increase despite industry efforts , 2017, Nature Reviews Drug Discovery.
[7] A. Kesselheim,et al. Progress and Hurdles for Follow-on Biologics. , 2015, The New England journal of medicine.
[8] W. Price,et al. Are trade secrets delaying biosimilars? , 2015, Science.
[9] Joseph A DiMasi,et al. Economics of new oncology drug development. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.